Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.
Frequently asked questions
What sector does Filament Health Corp (FH) operate in?
Filament Health Corp belongs to the Healthcare sector and operates in the industry.
What is Filament Health Corp (FH) current stock price?
As of the latest data, Filament Health Corp stock price is CA$0.01, with a previous close of CA$0.01.
What is Filament Health Corp (FH) current market capitalization?
Filament Health Corp market cap is approximately 2.62 million.
What is Filament Health Corp (FH) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.02.
Does Filament Health Corp (FH) pay dividends?
No. Filament Health Corp does not pay a dividend.
What is Filament Health Corp (FH) beta (volatility) score?
Filament Health Corp has a beta of 0.911, meaning its volatility is roughly in line with the market.
